Optimal strategies for identifying kidney disease in diabetes: Properties of screening tests, progression of renal dysfunction and impact of treatment - Systematic review and modelling of progression and cost-effectiveness

Health Technology Assessment

Volumn 18, Issue 14, 2014, Pages 1-127

  Farmer, Andrew J ^a   Stevens, Richard ^a   Hirst, Jennifer ^a   Lung, Tom ^b   Oke, Jason ^a   Clarke, Philip ^b   Glasziou, Paul ^c   Neil, Andrew ^d   Dunger, David ^e   Colhoun, Helen M ^f   Pugh, Christopher ^g   Wong, Germain ^h   Perera, Rafael ^a   Shine, Brian ⁱ  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BOND UNIVERSITY   (Australia)

^d WOLFSON COLLEGE   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NIFEDIPINE; OLMESARTAN; PENTOXIFYLLINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; TEMOCAPRIL; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ARTICLE; CARDIOVASCULAR DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIAGNOSTIC ACCURACY; DISEASE MARKER; DISEASE SURVEILLANCE; DRUG DOSE TITRATION; END STAGE RENAL DISEASE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MEASUREMENT ERROR; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SCREENING TEST; SIMULATION; SYSTEMATIC REVIEW;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIAGNOSTIC TESTS, ROUTINE; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS;

EID: 84895742355     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18140     Document Type: Article

References (228)

1. de Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med 2011;171:412-20. http://dx.doi.org/10.1001/ archinternmed.2011.16
2. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6. http://dx.doi.org/10.1001/jama.286.4.421
3. Thomas MC, Viberti G, Groop PH. Screening for chronic kidney disease in patients with diabetes: are we missing the point? Nat Clin Pract Nephrol 2008;4:2-3. http://dx.doi.org/10.1038/ ncpneph0679
4. Newman DJ, Mattock MB, Dawnay ABS, Kerry S, McGuire A, Yaqoob M, et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005;9(30).
5. Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess 2010;14(21).
6. Drury PL, Ting R, Zannio D, Ehnholm C, Flack J, Whiting M, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011;54:32-43. http://dx.doi.org/10.1007/s00125-010-1854-1
7. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulindependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-18. http://dx.doi.org/10.1001/archinte.157.13.1413
8. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40. http://dx.doi.org/10.1016/S0140-6736(11)60679-X
9. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-51.
10. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 2007;30:2523-8. http://dx.doi. org/10.2337/dc07-0282
11. Groop PH, Thomas MC, Moran JL, Waden J, Thorn LM, Makinen VP, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-8. http://dx.doi.org/10.2337/db08-1543
12. Gordois A, Scuffham P, Shearer A, Oglesby A. The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 2004;18:18-26. http://dx.doi.org/10.1016/S1056-8727(03)00035-7
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70. http://dx.doi.org/10.7326/0003-4819-130-6-199903160-00002
14. American Diabetes Association. Clinical Practice Recommendations 2009. Diabetes Care 2009;32(Suppl. 1).
15. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, et al. National Kidney Foundation's kidney disease outcomes quality initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003;111:1416-21. http://dx.doi.org/10.1542/peds.111.6.1416
16. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011;34:e61-99. http://dx.doi.org/10.2337/dc11-9998
17. Connell SJ, Hollis S, Tieszen KL, McMurray JR, Dornan TL. Gender and the clinical usefulness of the albumin: creatinine ratio. Diabet Med 1994;11:32-6. http://dx.doi.org/10.1111/ j.1464-5491.1994.tb00226.x
18. Amin R, Widmer B, Prevost AT, Schwarze P, Cooper J, Edge J, et al. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 2008;336:697-701. http://dx.doi.org/10.1136/bmj.39478.378241.BE
19. The National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (update). London: Royal College of Physicians; 2008.
20. Bank N. Mechanisms of diabetic hyperfiltration. Kidney Int 1991;40:792-807. http://dx.doi.org/ 10.1038/ki.1991.277
21. Mogensen CE, Poulsen PL. Microalbuminuria, glycemic control, and blood pressure predicting outcome in diabetes type 1 and type 2. Kidney Int Suppl 2004;92:S40-1. http://dx.doi.org/ 10.1111/j.1523-1755.2004.09210.x
22. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32. http://dx.doi.org/10.1046/j.1523-1755.2003.00712.x
23. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000;160:1093-100. http://dx.doi.org/10.1001/archinte.160.8.1093
24. MacIsaac RJ, Panagiotopoulos S, McNeil KJ, Smith TJ, Tsalamandris C, Hao H, et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 2006;29:1560-6. http://dx.doi.org/10.2337/dc05-1788
25. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-7. http://dx.doi. org/10.1001/jama.289.24.3273
26. New JP, Middleton RJ, Klebe B, Farmer CK, de Lusignan S, Stevens PE, et al. Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabet Med 2007;24:364-9. http://dx. doi.org/10.1111/j.1464-5491.2007.02075.x
27. Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, Nathan DM, et al. Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care 2008;31:2338-43. http://dx.doi.org/10.2337/dc08-0277
28. Bilous R, Chaturvedi N, Sjolie AK, Fuller J, Klein R, Orchard T, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-20. http://dx.doi.org/10.7326/0003-4819-151-1-200907070-00120
29. Rossing P, Hougaard P, Parving H. Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int 2005;68:1446-50. http://dx.doi.org/ 10.1111/j.1523-1755.2005.00556.x
30. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81. http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00001
31. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997;20:1576-81. http://dx.doi.org/10.2337/diacare.20.10.1576
32. Christensen CK, Mogensen CE. The course of incipient diabetic nephropathy: studies of albumin excretion and blood pressure. Diabet Med 1985;2:97-102. http://dx.doi.org/10.1111/ j.1464-5491.1985.tb00608.x
33. Vergouwe Y, Soedamah-Muthu SS, Zgibor J, Chaturvedi N, Forsblom C, Snell-Bergeon JK, et al. Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule. Diabetologia 2010;53:254-62. http://dx.doi.org/10.1007/s00125-009-1585-3
34. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008;31:2198-202. http://dx.doi.org/10.2337/dc08-0864
35. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 2001;60:219-27. http://dx.doi.org/ 10.1046/j.1523-1755.2001.00789.x
36. Waden J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH, et al. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 2009;58:2649-55. http://dx.doi.org/10.2337/db09-0693
37. Royal College of Physicians of Edinburgh Diabetes Register Group. Near-normal urinary albumin concentrations predict progression to diabetic nephropathy in Type 1 diabetes mellitus. Diabetic Med 2000;17:782-91.
38. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002;25:859-64. http://dx.doi.org/10.2337/diacare.25.5.859
39. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55:1832-9. http://dx.doi.org/10.2337/db05-1620
40. Amini M, Safaei H, Aminorroaya A. The incidence of microalbuminuria and its associated risk factors in type 2 diabetic patients in Isfahan, Iran. Rev Diabet Stud 2007;4:242. http://dx.doi.org/ 10.1900/RDS.2007.4.242
41. Agrawal L, Azad N, Emanuele NV, Bahn GD, Kaufman DG, Moritz TE, et al. Observation on renal outcomes in the Veterans Affairs Diabetes Trial. Diabetes Care 2011;34:2090-4. http://dx.doi.org/ 10.2337/dc11-0175
42. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, et al. Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato study. Diabetes Care 2003;26:2150-5. http://dx.doi.org/10.2337/diacare.26.7.2150
43. Xu J, Lee ET, Devereux RB, Umans JG, Bella JN, Shara NM, et al. A longitudinal study of risk factors for incident albuminuria in diabetic American Indians: the Strong Heart Study. Am J Kidney Dis 2008;51:415-24. http://dx.doi.org/10.1053/j.ajkd.2007.11.010
44. Chandie Shaw PK, Baboe F, van Es LA, van der Vijver JC, van de Ree MA, de Jonge N, et al. South-Asian type 2 diabetic patients have higher incidence and faster progression of renal disease compared with Dutch-European diabetic patients. Diabetes Care 2006;29:1383-5. http://dx.doi.org/10.2337/dc06-0003
45. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
46. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994;17:126-31. http://dx.doi.org/ 10.2337/diacare.17.2.126
47. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33. http://dx.doi.org/10.1056/NEJM199910073411506
48. Schultz CJ, Konopelska-Bahu T, Dalton RN, Carroll TA, Stratton I, Gale EA, et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care 1999;22:495-502. http://dx.doi.org/10.2337/diacare.22.3.495
49. Burden AC, McNally PG, Feehally J, Walls J. Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diabet Med 1992;9:641-5. http://dx.doi.org/10.1111/j.1464-5491.1992.tb01860.x
50. Roderick PJ, Raleigh VS, Hallam L, Mallick NP. The need and demand for renal replacement therapy in ethnic minorities in England. J Epidemiol Community Health 1996;50:334-9. http://dx.doi.org/10.1136/jech.50.3.334
51. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010;53:2312-19. http://dx.doi.org/10.1007/s00125-010-1860-3
52. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983;32(Suppl. 2):64-78. http://dx.doi. org/10.2337/diab.32.2.S64
53. Gall MA, Rossing P, Skott P, Damsbo P, Vaag A, Bech K, et al. Prevalence of micro-and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991;34:655-61. http://dx.doi.org/ 10.1007/BF00400995
54. Jørgensen L, Heuch I, Jenssen T, Jacobsen BK. Association of albuminuria and cancer incidence. J Am Soc Nephrol 2008;19:992-8. http://dx.doi.org/10.1681/ASN.2007060712
55. Wong G, Hayen A, Chapman JR, Webster AC, Wang JJ, Mitchell P, et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009;20:1341-50. http://dx.doi.org/10.1681/ ASN.2008090998
56. Drion I, van Hateren KJ, Joosten H, Alkhalaf A, Groenier KH, Kleefstra N, et al. Chronic kidney disease and mortality risk among older patients with type 2 diabetes mellitus (ZODIAC-24). Age Ageing 2012;41:345-50. http://dx.doi.org/10.1093/ageing/afs002
57. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
58. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
59. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61.
60. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). UK Prospective Diabetes Study (UKPDS) Group. BMJ 1998;317:703-13.
61. de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-92. http://dx.doi.org/ 10.1681/ASN.2008070667
62. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
63. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2005;4:CD004136. http://dx.doi.org/10.1002/14651858.CD004136
64. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-51. http://dx.doi.org/10.1136/bmj.39472.580984.AE
65. Nagrebetsky A, Jin J, Stevens R, James T, Adler A, Park P, et al. Diagnostic accuracy of urine dipstick testing in screening for microalbuminuria in type 2 diabetes: a cohort study in primary care. Fam Pract 2013;30:142-52. http://dx.doi.org/10.1093/fampra/cms057
66. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl. 1):S1-266.
67. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ 2011;343:d7163. http://dx.doi.org/10.1136/bmj.d7163
68. Clarke PM, Gray AM, Briggs A, Farmer A, Fenn P, Stevens R, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59. http://dx.doi.org/10.1007/s00125-004-1527-z
69. Wirta OR, Pasternack AI, Mustonen JT, Koivula TA, Harmoinen A. Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients. Nephrol Dial Transplant 1996;11:449-56. http://dx.doi.org/10.1093/oxfordjournals.ndt.a027310
70. Niskanen L, Voutilainen R, Terasvirta M, Lehtinen J, Teppo AM, Groop L, et al. A prospective study of clinical and metabolic associates of proteinuria in patients with type 2 diabetes mellitus. Diabet Med 1993;10:543-9. http://dx.doi.org/10.1111/j.1464-5491.1993.tb00118.x
71. HOPE Study Investigators, Gerstein HC, Yusuf S, Mann JFE, Hoogwerf B, Zinman B, et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
72. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60. http://dx.doi.org/10.1056/NEJMoa011303
73. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Oxford: Wiley; 2008.
74. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. http://dx.doi.org/10.1016/0197-2456(86)90046-2
75. Friedrich JO, Adhikari NK, Beyene J. Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. J Clin Epidemiol 2011;64:556-64. http://dx.doi.org/10.1016/j.jclinepi.2010.09.016
76. Friedrich J, Adhikari N, Beyene J. The ratio of means method as an alternative to mean differences for analysing continuous outcome variables in meta-analysis: a simulation study. BMC Med Res Methodol 2008;8:32. http://dx.doi.org/10.1186/1471-2288-8-32
77. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48. http://dx.doi.org/10.7326/0003-4819-148-1-200801010-00190
78. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int 1992;41:912-9. http://dx.doi.org/10.1038/ ki.1992.139
79. Cordonnier DJ, Pinel N, Barro C, Maynard C, Zaoui P, Halimi S, et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 1999;10:1253-63.
80. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994;45:S150-5.
81. Crepaldi G, Carraro A, Brocco E, Adezati L, Andreani D, Bompiani G, et al. Hypertension and non-insulin-dependent diabetes-a comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist. Acta Diabetol 1995;32:203-8. http://dx.doi.org/10.1007/ BF00838494
82. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51. http://dx.doi.org/ 10.1056/NEJMoa0808400
83. Muirhead N, Feagan BF, Mahon J, Lewanczuk RZ, Rodger NW, Botteri F, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Therapeutic Res 1999;60:650-60. http://dx.doi.org/10.1016/ S0011-393X(99)90003-6
84. Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S, et al. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 2007;30:325-34. http://dx.doi.org/10.1291/ hypres.30.325
85. EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID study group. Lancet 1997;349:1787-92.
86. Baba S, Koike T, Makino I, Maruhama Y, Sasaki H, Goto Y, et al. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001;54:191-201. http://dx.doi.org/10.1016/S0168-8227(01)00288-1
87. Chan JCN, Ko GTC, Leung DHY, Cheung RCK, Cheung MYF, So WY, et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000;57:590-600. http://dx.doi.org/10.1046/j.1523-1755.2000.00879.x
88. Sawaki H, Terasaki J, Fujita A, Nakagawa S, Kanatsuna N, Sadahiro K, et al. A renoprotective effect of low dose losartan in patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:86-90. http://dx.doi.org/10.1016/j.diabres.2007.08.004
89. Perrin NESS, Jaremko GA, Berg UB. The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial. Pediatr Nephrol 2008;23:947-54. http://dx.doi.org/ 10.1007/s00467-008-0745-x
90. Tuominen JA, Ebeling P, Koivisto VA. Long-term lisinopril therapy reduces exercise-induced albuminuria in normoalbuminuric normotensive IDDM patients. Diabetes Care 1998;21:1345-8. http://dx.doi.org/10.2337/diacare.21.8.1345
91. Kvetny J, Gregersen G, Pedersen RS. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. QJM 2001;94:89-94. http://dx.doi.org/10.1093/qjmed/94.2.89
92. Garg SK, Chase HP, Jackson WE, Harris S, Carmain JA, Hansen MH, et al. Renal and retinal changes after treatment with ramipril and pentoxifylline in subjects with IDDM. Ann Ophthalmol Glaucoma 1998;30:33-7.
93. Bakris GL, Slataper R, Vicknair N, Sadler R. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabetes Complications 1994;8:2-6. http://dx.doi.org/10.1016/1056-8727(94)90003-5
94. O'Hare P, Bilbous R, Mitchell T, O'Callaghan CJ, Viberti GC, Ace-inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects Study Group. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 2000;23:1823-9.
95. Bojestig M, Karlberg BE, Lindström T, Nystrom FH. Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care 2001;24:919-24. http://dx.doi.org/10.2337/diacare.24.5.919
96. Chase H, Garg S, Harris S, Hoops S, Jackson W, Holmes D. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993;25:284.
97. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995;99:497-504. http://dx.doi.org/10.1016/S0002-9343(99)80226-5
98. Poulsen P, Ebbehøj E, Mogensen CE. Lisinopril reduces albuminuria during exercise in low grade microalbuminuric type 1 diabetic patients: a double blind randomized study. J Intern Med 2001;249:433-40. http://dx.doi.org/10.1046/j.1365-2796.2001.00821.x
99. Viberti G, Mogensen CE, Groop LC, Pauls JF, Boner G, van Dyk D, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-9. http://dx.doi.org/10.1001/ jama.1994.03510280037029
100. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 2001;37:890-9. http://dx.doi.org/10.1016/S0272-6386 (05)80003-4
101. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. http://dx.doi.org/10.1056/ NEJM199311113292004
102. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998;21:104-10. http://dx.doi.org/ 10.2337/diacare.21.1.104
103. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving H. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999;319:24-5. http://dx.doi.org/10.1136/ bmj.319.7201.24
104. Ahmad J, Shafique S, Abidi S, Parwez I. Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract 2003;60:131. http://dx.doi.org/10.1016/S0168-8227(03)00016-0
105. Parving H, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001;60:228-34. http://dx.doi.org/10.1046/j.1523-1755.2001.00790.x
106. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51. http://dx.doi.org/10.1056/NEJMoa042167
107. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17. http://dx.doi. org/10.1056/NEJMoa1007994
108. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 2009;32:2068-74. http://dx.doi.org/10.2337/dc09-0959
109. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40. http://dx.doi.org/10.1016/S0140-6736(07)61303-8
110. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-8. http://dx.doi.org/10.7326/ 0003-4819-128-12_Part_1-199806150-00004
111. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.
112. Romero R, Salinas I, Lucas A, Abad E, Reverter JL, Johnston S, et al. Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors. Diabetes Care 1993;16:597-600. http://dx.doi.org/10.2337/diacare.16.4.597
113. Uzu T, Sawaguchi M, Maegawa H, Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes mellitus: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007;30:1581-3.
114. Tan KC, Chow W, Ai VH, Lam KS. Effects of angiotensin II receptor antagonist on endothelial vasomotor function and urinary albumin excretion in type 2 diabetic patients with microalbuminuria. Diabetes Metab Res 2002;18:71-6. http://dx.doi.org/10.1002/dmrr.255
115. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. Am J Hypertens 1995;8:876-83. http://dx.doi.org/10.1016/0895-7061(95)00162-I
116. Rodríguez-Morán M, Guerrero-Romero F. Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients-a randomized, equivalent trial. Clin Nephrol 2005;64:91-7.
117. de Mello VD, Zelmanovitz T, Azevedo MJ, de Paula TP, Gross JL. Long-term effect of a chicken-based diet versus enalapril on albuminuria in type 2 diabetic patients with microalbuminuria. J Ren Nutr 2008;18:440-7. http://dx.doi.org/10.1053/j.jrn.2008.04.010
118. Puig JG, Marre M, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens 2007;20:90-7. http://dx.doi.org/10.1016/j.amjhyper.2006.05.018
119. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007;30:1577-8. http://dx.doi.org/10.2337/dc06-1998
120. Tong P, Ko G, Chan W, Ma R, So W, Lo M, et al. The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency. Diabetes Obes Metab 2006;8:342-7. http://dx.doi.org/10.1111/j.1463-1326.2005.00514.x
121. Parving H, Lehnert H, Brochner-Mortensen JF, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8. http://dx.doi.org/10.1056/NEJMoa011489
122. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau J, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003;138:542-9. http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00010
123. de Zeeuw D, Remuzzi G, Parving H, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20. http://dx.doi.org/10.1111/j.1523-1755.2004.00653.x
124. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Ménard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004;328:495. http://dx.doi.org/10.1136/bmj.37970.629537.0D
125. Sano T, Hotta N, Kawamura T, Matsumae H, Chaya S, Sasaki H, et al. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. Diabetic Med 1996;13:120-4. http://dx.doi. org/10.1002/(SICI)1096-9136(199602)13:2<120::AID-DIA6>3.3.CO;2-6
126. Strippoli GFM, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006;:CD006257. http://dx.doi.org/10.1002/ 14651858.CD006257
127. Riley RD, Gates S, Neilson J, Alfirevic Z. Statistical methods can be improved within Cochrane pregnancy and childbirth reviews. J Clin Epidemiol 2011;64:608-18. http://dx.doi.org/10.1016/ j.jclinepi.2010.08.002
128. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33. http://dx.doi.org/10.1016/ S0140-6736(05)67814-2
129. Gerstein HC. Diabetes and the HOPE study: implications for macrovascular and microvascular disease. Int J Clin Prac Suppl 2001;117:8-12.
130. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, Cooper ME, Parving HH, Shahinfar S, et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 2010;21:1355-60. http://dx.doi.org/10.1681/ASN.2010010063
131. Yudkin JS, Lehman R. Olmesartan, microalbuminuria, and type 2 diabetes. N Engl J Med 2011;364:2260; author reply 2262-3.
132. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012;55:566-78. http://dx.doi.org/10.1007/ s00125-011-2398-8
133. Rosen AB. Indications for and utilization of ACE inhibitors in older individuals with diabetes: findings from the national health and nutrition examination survey 1999 to 2002. J Gen Intern Med 2006;21:315-9. http://dx.doi.org/10.1111/j.1525-1497.2006.00351.x
134. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A; LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 2008;148:656-61. http://dx.doi.org/10.7326/0003-4819-148-9-200805060-00005
135. Keenan K, Hayen A, Neal BC, Irwig L. Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. BMJ 2009;338:b1492. http://dx.doi.org/10.1136/bmj.b1492
136. Takahashi O, Farmer AJ, Shimbo T, Fukui T, Glasziou PP. A1C to detect diabetes in healthy adults: when should we recheck? Diabetes Care 2010;33:2016-17. http://dx.doi.org/10.2337/dc10-0588
137. Oke JL, Stevens R, Gaitskell K, Farmer A. Establishing an evidence base for frequency of monitoring glycated haemoglobin levels in patients with type 2 diabetes: projections of effectiveness from a regression model. Diabet Med 2012;29:266-71. http://dx.doi.org/10.1111/ j.1464-5491.2011.03412.x
138. Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 1985;106:522-6. http://dx.doi.org/10.1016/S0022-3476(85)80697-1
139. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-A Bayesian modelling framework: concepts, structure and extensibility. Stat Comput 2000;10:325-37.
140. Stevens RJ, Oke J, Perera R. Statistical models for the control phase of clinical monitoring. Stat Methods Med Res 2010;19:394-414. http://dx.doi.org/10.1177/0962280209359886
141. Alleyn CR, Volkening LK, Wolfson J, Rodriguez-Ventura A, Wood JR, Laffel LM. Occurrence of microalbuminuria in young people with type 1 diabetes: importance of age and diabetes duration. Diabet Med 2010;27:532-7. http://dx.doi.org/10.1111/j.1464-5491.2010.02983.x
142. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983;25:496-501. http://dx.doi.org/10.1007/BF00284458
143. Cho YH, Craig ME, Hing S, Gallego PH, Poon M, Chan A, et al. Microvascular complications assessment in adolescents with 2-to 5-yr duration of type 1 diabetes from 1990 to 2006. Pediatr Diabetes 2011;12:682-9. http://dx.doi.org/10.1111/j.1399-5448.2011.00762.x
144. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004;328:1105. http://dx.doi.org/10.1136/bmj.38070.450891.FE
145. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type I diabetes. Am J Med 1985;78:785-94. http://dx.doi.org/10.1016/0002-9343 (85)90284-0
146. Salgado PP, Silva IN, Vieira EC, Simões Silva AC. Risk factors for early onset of diabetic nephropathy in pediatric type 1 diabetes. J Pediatr Endocrinol Metab 2010;23:1311-20.
147. Tryggvason G, Indridason OS, Thorsson AV, Hreidarsson AB, Palsson R. Unchanged incidence of diabetic nephropathy in type 1 diabetes: a nation-wide study in Iceland. Diabet Med 2005;22:182-7. http://dx.doi.org/10.1111/j.1464-5491.2004.01390.x
148. National Institute for Health and Care Excellence. Clinical guideline 15: type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults. Manchester: NICE; 2004.
149. Adolescent Type 1 Diabetes Cardio-renal Intervention Trial Research Group. Adolescent type 1 diabetes cardio-renal intervention trial (AdDIT). BMC Pediatr 2009;9:79.
150. Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, De Boer IH, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010;33:1536-43. http://dx.doi.org/10.2337/dc09-1098
151. Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN, et al. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002;19:201-11. http://dx.doi.org/10.1046/j.1464-5491.2002.00643.x
152. Thomason MJ, Colhoun HM, Livingstone SJ, Mackness MI, Betteridge DJ, Durrington PN, et al. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabetic Med 2004;21:901-5. http://dx.doi.org/10.1111/j.1464-5491. 2004.01401.x
153. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative AtoRvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. http://dx.doi.org/10.1016/S0140-6736(04)16895-5
154. Escobedo J, Rana JS, Lombardero MS, Albert SG, Davis AM, Kennedy FP, et al. Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D study. Mayo Clin Proc 2010;85:41-6. http://dx.doi.org/10.4065/mcp.2009.0265
155. Park JY, Kim HK, Chung YE, Kim SW, Hong SK, Lee KU. Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. Diabetes Care 1998;21:530-4. http://dx.doi. org/10.2337/diacare.21.4.530
156. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638-46.
157. American Diabetes Association. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5.
158. Wu SY, Sainfort F, Tomar RH, Tollios JL, Fryback DG, Klein R, et al. Development and application of a model to estimate the impact of type 1 diabetes on health-related quality of life. Diabetes Care 1998;21:725-31. http://dx.doi.org/10.2337/diacare.21.5.725
159. Meltzer D, Egleston B, Stoffel D, Dasbach E. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med Care 2000;38:679-85. http://dx.doi.org/10.1097/00005650-200006000-00009
160. Tomar RH, Lee S, Wu SY, Klein R, Klein BE, Moss SE, et al. Disease progression and cost of insulin dependent diabetes mellitus: development and application of a simulation model. J Soc Health Systems 1998;5:24-37.
161. Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin 2004;20:1729-46. http://dx.doi.org/10.1185/030079904X5661
162. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease-a systematic review of tools for clinicians. J Gen Intern Med 2003;18:1039-52. http://dx.doi.org/10.1111/j.1525-1497.2003.30107.x
163. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001;101:671-9. http://dx.doi.org/10.1042/CS20000335
164. Zgibor JC, Piatt GA, Ruppert K, Orchard TJ, Roberts MS. Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care 2006;29:1860-5.
165. Oke J, Stevens RJ, Perera R, Dunger D, Dalton N, Neil A, et al. Current and alternative programmes for monitoring renal function in type 1 diabetes: modelling study based on the Oxford Regional Prospective Study. Prim Health Care Res Dev 2010;11(Suppl. 1):43.
166. Hayes AJ, Leal J, Kelman CW, Clarke PM. Risk equations to predict life expectancy of people with type 2 diabetes mellitus following major complications: a study from Western Australia. Diabet Med 2011;28:428-35. http://dx.doi.org/10.1111/j.1464-5491.2010.03189.x
167. Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005;294:1782-7. http://dx.doi.org/10.1001/ jama.294.14.1782
168. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002;105:1354-9. http://dx.doi.org/10.1161/hc1102.105261
169. Kelly PK, Clarke PM, Hayes AJ, Gerdtham UG, Nilsson PM, Eliasson B, et al. Predicting the mortality of people with type 2 diabetes mellitus following a major complication: a study using Swedish Nation Diabetes Register Data. Diabetologia 2011;54(Suppl. 1):S1-542.
170. Lung TW, Hayes AJ, Hayen A, Farmer A, Clarke PM. A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Qual Life Res 2011;20:1669-78. http://dx.doi.org/10.1007/s11136-011-9902-y
171. U.S. Department of Health and Human Services. Vital Statistics of the United States, 1991: Life Tables. Vol. II, Section 6. Hyattsville, MD: Center for Disease Control and Prevention; 1995.
172. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. http://dx.doi.org/10.1186/ 1745-6215-8-16
173. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2006;368:1420.
174. Olshansky SJ, Carnes BA. Limits on lifetimes: ever since Gompertz. Demography 1997;34:1-15.
175. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. Diabetologia 2006;49:660-6. http://dx.doi.org/10.1007/s00125-005-0120-4
176. Office for National Statistics. 2009 Population Estimates: quinary age groups for primary care organisations in England; estimated resident population. Office for National Statistics; 2011. URL: http://www.statistics.gov.uk (accessed 9 October 2011).
177. Podar T, Solntsev A, Reunanen A, Urbonaite B, Zalinkevicius R, Karvonen M, et al. Mortality in patients with childhood-onset type 1 diabetes in Finland, Estonia, and Lithuania-follow-up of nationwide cohorts. Diabetes Care 2000;23:290-4.
178. McNally PC, Raymond NT, Burden ML, Burton PR, Botha JL, Swift PGF, et al. Trends in mortality of childhood-onset insulin-dependent diabetes-mellitus in Leicestershire 1940-1991. Diabet Med 1995;12:961-6. http://dx.doi.org/10.1111/j.1464-5491.1995.tb00406.x
179. Nishimura R, LaPorte RE, Dorman JS, Tajima N, Becker D, Orchard TJ. Mortality trends in type 1 diabetes-the Allegheny County (Pennsylvania) Registry 1965-1999. Diabetes Care 2001;24:823-7. http://dx.doi.org/10.2337/diacare.24.5.823
180. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003;46:760-5. http://dx.doi.org/10.1007/s00125-003-1116-6
181. Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County Type 1 Diabetes Registry. Diabetes Care 2010;33:2573-9. http://dx.doi.org/10.2337/ dc10-1170
182. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Gudbjornsdottir S; Swedish National Diabetes Register. A new model for 5-year risk of cardiovascular disease in type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med 2011;28:1213-20. http://dx.doi.org/ 10.1111/j.1464-5491.2011.03342.x
183. Zgibor JC, Ruppert K, Orchard TJ, Soedamah-Muthu SS, Fuller J, Chaturvedi N, et al. Development of a coronary heart disease risk prediction model for type 1 diabetes: the Pittsburgh CHD in type 1 diabetes risk model. Diabetes Res Clin Prac 2010;88:314-21. http://dx.doi.org/ 10.1016/j.diabres.2010.02.009
184. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89. http://dx.doi.org/10.1056/ NEJMoa0806470
185. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int 2002;61: 2165-75. http://dx.doi.org/10.1046/j.1523-1755.2002.00356.x
186. Her Majesty's Treasury. The Green Book: Appraisal and Evaluation in Central Government. London: Stationery Office; 2011.
187. National Institute for Health and Care Excellence. Chronic kidney disease costing report: implementing NICE guidance. London: National Institute for Health and Care Excellence; 2008.
188. Curtis L. Unit costs of health and social care 2010. Canterbury: Personal Social Services Research Unit, University of Kent; 2010.
189. Department of Health. Prescription cost analysis England 2010. London: Department of Health; 2010.
190. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003;20:442-50. http://dx.doi.org/10.1046/j.1464-5491.2003.00972.x
191. Klebe B, Irving J, Stevens PE, O'Donoghue DJ, de Lusignan S, Cooley R, et al. The cost of implementing UK guidelines for the management of chronic kidney disease. Nephrol Dial Transplant 2007;22:2504-12. http://dx.doi.org/10.1093/ndt/gfm248
192. National Institute for Health and Care Excellence. Chronic kidney disease in adults: UK guidelines for identification, management and referral. Leeds: National Institute for Health and Care Excellence; 2011.
193. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 2006;6:52.
194. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions-standardizing data on outcomes. N Engl J Med 1998;339:380-6. http://dx.doi.org/10.1056/ NEJM199808063390606
195. Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-77. http://dx.doi.org/10.1007/s00125-005-1717-3
196. Glasziou PP, Clarke P, Alexander J, Rajmokan M, Beller E, Woodward M, et al. Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis. Med J Aust 2010;193:320-4.
197. Yang XL, So WY, Kong AP, Clarke P, Ho CS, Lam CW, et al. End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia 2006;49:2299-308. http://dx.doi.org/10.1007/s00125-006-0376-3
198. Bossuyt PM, Lijmer JG, Mol BW. Randomised comparisons of medical tests: sometimes invalid, not always efficient. Lancet 2000;356:1844-7. http://dx.doi.org/10.1016/S0140-6736(00)03246-3
199. American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5.
200. Marshall SM. Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s? Diabetologia 2012;55:2301-6. http://dx.doi.org/10.1007/s00125-012-2606-1
201. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005;16:1404-12. http://dx.doi.org/10.1681/ASN.2004100854
202. Perkins BA, Krolewski AS. Early nephropathy in type 1 diabetes: a new perspective on who will and who will not progress. Curr Diab Rep 2005;5:455-63. http://dx.doi.org/10.1007/ s11892-005-0055-7
203. Premaratne E, MacIsaac RJ, Finch S, Panagiotopoulos S, Ekinci E, Jerums G. Serial measurements of cystatin C are more accurate than creatinine-based methods in detecting declining renal function in type 1 diabetes. Diabetes Care 2008;31:971-3. http://dx.doi.org/10.2337/dc07-1588
204. Aung T, Cowan H, Haynes R, Bowman L, Armitage J. Recruiting patients cost-effectively by mail. Trials 2011;12(Suppl. 1):A117. http://dx.doi.org/10.1186/1745-6215-12-S1-A117
205. Scognamiglio R, Nosadini R, Marin M, Nisti S, Fasoli G, Palisi M, et al. Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive type 2 diabetic patients. Diabetes Care 1997;20:1290-2. http://dx.doi.org/10.2337/ diacare.20.8.1290
206. Parving H, Hommel E, Nielsen MD, Giese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 1989;299:533. http://dx.doi.org/10.1136/bmj.299.6698.533
207. Capek M, Schnack C, Ludvik B, Kautzky-Willer A, Banyai M, Prager R. Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study. Clin Investig 1994;72:961-6. http://dx.doi.org/10.1007/BF00577736
208. Tütüncü N, Gürlek A, Gedik O. Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol 2001;38:157-61.
209. Stornello M, Valvo E, Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol 1989;14:851-5. http://dx.doi.org/10.1097/ 00005344-198912000-00009
210. Stornello M, Valvo EV, Scapellato L. Persistent albuminuria in normotensive non-insulindependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers. Clin Sci 1992;82:19-23.
211. Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996;45:216-22. http://dx.doi.org/10.2337/diabetes.45.2.216
212. Rizzoni D, Porteri E, De Ciuceis C, Sleiman I, Rodella L, Rezzani R, et al. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension 2005;45:659-65. http://dx.doi.org/ 10.1161/01.HYP.0000153308.91043.97
213. Ko GT, Tsang C, Chan HC. Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril. Adv Ther 2005;22:155-62. http://dx.doi.org/10.1007/BF02849886
214. Lacourcière Y, Bélanger A, Godin C, Hallé J, Ross S, Wright N, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58:762-9. http://dx.doi.org/10.1046/j.1523-1755.2000.00224.x
215. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61. http://dx.doi.org/10.1056/NEJMoa042274
216. Schrier R, Estacio R, Jeffers B. Appropriate blood pressure control in NIDDM (ABCD) trial. Diabetologia 1996;39:1646-54. http://dx.doi.org/10.1007/s001250050629
217. Joglekar SJ, Nanivadekar AS. A randomized, controlled, multicenter study to compare prazosin GITS with enalapril in hypertensive patients with diabetes mellitus. Bombay Hypertension Study Group. J Assoc Physicians India 1998;(Suppl. 1):52-62.
218. Lin M, Yang YF, Chiang HT, Lee D, Wang SP, Chang MS, et al. Beneficial effects of angiotensinconverting enzyme inhibitors on cardiovascular and renal functions in patients with hypertension and diabetes. Acta Cardiol Sin 1995;11:30-8.
219. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603. http://dx.doi.org/10.2337/ diacare.21.4.597
220. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
221. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992;41:912-19. http://dx.doi.org/10.1038/ ki.1992.139
222. Marre M, Leblanc H, Suarez L, Guyenne TT, Menard J, Passa P. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J 1987;294:1448. http://dx.doi.org/10.1136/bmj.294.6585.1448
223. Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin F. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metab Clin Exp 1998;47(Suppl. 1):12-15. http://dx.doi.org/10.1016/S0026-0495(98)90364-X
224. O'Donnell MJ, Rowe BR, Lawson N, Horton A, Gyde OH, Barnett AH. Placebo-controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 1993;7:327-32.
225. Phillips PJ, Phillipou G, Bowen KM, Lowe J, Yue DK, Wischusen J, et al. Diabetic microalbuminuria and cilazapril. Am J Med 1993;94:58S-60S.
226. Sato A, Tabata M, Hayashi K, Saruta T. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy. J Clin Experi Nephrol 2003;7:215-20. http://dx.doi.org/10.1007/s10157-003-0227-1
227. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45.
228. Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial (DCCT) Research Group. Kidney Int 1995;47:1703-20.